NewsBenzingaXBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing... XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing... Benzinga 2026.10.19 13:03 (GMT+0) Open on Benzinga Other news Circle's Arc blockchain launches Arc Portal ecosystem hub Meta, IBM, Texas Instruments, LAM Research and Tesla: Why These 5 Stocks Are on Investors' Radars Today Kling's New Model Kling 4.0 API Officially Launches SEC announces 3 companies planning to operate tokenized securities trading platforms under new Innovation Exemption This wonky maneuver kept Mark Zuckerberg from fleeing a California billionaire tax WD-40 Company (WDFC) Q4 2026 Earnings Call Transcript
Meta, IBM, Texas Instruments, LAM Research and Tesla: Why These 5 Stocks Are on Investors' Radars Today
SEC announces 3 companies planning to operate tokenized securities trading platforms under new Innovation Exemption
